Burrill

Norwest Venture Partners Hires Zack Scott as General Partner on Healthcare Investment Team

Retrieved on: 
Wednesday, September 21, 2022
Oregon Health and Science University Center for Women's Health, Fuqua, TigerConnect, Burrill, Oregon Health & Science University, Fuqua School of Business, Name, Company, University, Philosophy, Business, Investment, IPO, Fuqua School, Chief executive officer, Duke University, Norwest Venture Partners, General surgery, PALO, Multimedia, Financial services, Healthcare, Medical device, Norwest

PALO ALTO, Calif., Sept. 21, 2022 /PRNewswire/ -- Norwest Venture Partners , a leading venture capital and growth equity investment firm, announced today Zack Scott, M.D., has joined the investment team as general partner for the healthcare practice.

Key Points: 
  • PALO ALTO, Calif., Sept. 21, 2022 /PRNewswire/ -- Norwest Venture Partners , a leading venture capital and growth equity investment firm, announced today Zack Scott, M.D., has joined the investment team as general partner for the healthcare practice.
  • Dr. Scott joins Norwest from Revelation Partners, a dedicated secondary investor in the healthcare space, where he was a co-founder and managing partner.
  • "We're fortunate to have Zack join our team and contribute his years of experience in medical devices, diagnostics, healthcare services, and biopharmaceuticals to the firm and the portfolio," said Casper de Clercq, general partner, Norwest Venture Partners.
  • "I was drawn to Norwest's healthcare team because I believe its diversified investment philosophy will make a lasting, positive impact on the future of healthcare," said Dr. Scott, general partner, Norwest Venture Partners.

VYNE Therapeutics Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, October 21, 2021
Former, Veterans Health Administration, Neoplasm, Twitter, Skin, Cytokine, International Organization (journal), Minocycline, Disclosure, BET, Therapy, Division, GLOBE, American Academy, Nissin Dental Products, Inc., European Academy of Neurology, Research, Mount Sinai School, American Neurological Association, Crohn's disease, U.S. Securities and Exchange Commission, Penn Presbyterian Medical Center, Adapalene, Company, American College of Rheumatology, Burrill, Inflammatory bowel disease, Rosacea, Regulation Fair Disclosure, Fox Chase Cancer Center, CEO, Cancer, Nasdaq, American Academy of Neurology, Inflammation, Regulation, Patient, FDA, Board, University of Texas Southwestern Medical Center, Coronavirus Scientific Advisory Board (Turkey), American College, SAB, Pharmaceutical industry, Vaccine, Medical device

BRIDGEWATER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the formation of its Scientific Advisory Board (SAB) composed of leading scientists and clinicians specializing in immunological and inflammatory diseases.

Key Points: 
  • BRIDGEWATER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced the formation of its Scientific Advisory Board (SAB) composed of leading scientists and clinicians specializing in immunological and inflammatory diseases.
  • The SAB will provide scientific expertise and guidance to the VYNE management team and Board as the Company progresses its pipeline of innovative treatments for immuno-inflammatory conditions.
  • Iain Stuart, Chief Scientific Officer at VYNE, said The SABs immediate focus is our recently licensed BET inhibitor platform.
  • For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter.